Regeneron just snagged having its trial stopped for overwhelming efficacy in its COVID-19 treatment.
It already had an EUA in place.
That is what a successful trial looks like.
Why do the MSB holders think trial success comes from searching through the ruins of its failures.
You would have thought the failure of trying to convince the FDA that data from failed aGVHD trials and an industry databases might have been a light bulb moment.
Regeneron just snagged having its trial stopped for overwhelming...
-
- There are more pages in this discussion • 227 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.21 |
Change
0.040(3.42%) |
Mkt cap ! $1.381B | |||
| Open | High | Low | Value | Volume |
| $1.17 | $1.22 | $1.17 | $5.683M | 4.776M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | $1.21 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.21 | 19746 | 3 |
View Market Depth
| Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |